Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1495 • ACR Convergence 2023
Deep Serological Profiling of SLE Patients Treated with anti-CD19 CAR T Cells
Samik Basu¹, Daniel Nunez¹, Darshil Patel¹, Jenell Volkov¹, Zachary Vorndran¹, Steven Wong¹, Andreas Mackensen² and Georg Schett³, ¹Cabaletta Bio, Philadelphia, PA, ²Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a ground-breaking emerging treatment modality for severe refractory systemic lupus erythematosus (SLE) and has shown…
Abstract Number: 1579 • ACR Convergence 2023
Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus
April Jorge¹, Baijun Zhou¹, Natalie McCormick¹, Chio Yokose¹, Yuqing Zhang² and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2) have benefits on kidney and cardiovascular (CV) outcomes that are largely independent of glycemic control. These benefits have been demonstrated…
Abstract Number: 1625 • ACR Convergence 2023
Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning
santiago arciniegas¹, Matthias W. Wagner², Logi Vidarsson², Birgit Ertl-Wagner², Tala El Tal³, Asha Jeyanathan², Lawrence Ng², Linda Hiraki², Deborah Levy², George M. Ibrahim² and Andrea Knight², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Childhood-onset SLE (cSLE) is characterised by a higher frequency of nervous system involvement, known…
Abstract Number: 1852 • ACR Convergence 2023
Human Papillomavirus Vaccine Uptakes in Ethnically Diverse Women Living with Systemic Lupus Erythematosus
Sebastian Bruera¹, Yinan Huang², Savannah Bowman¹, Maria Suarez-Almazor³, Grace Lo¹, Maria A. Lopez-Olivo⁴ and Sandeep Agarwal¹, ¹Baylor College of Medicine, Houston, TX, ²Department of Pharmacy Administration, University of Mississippi School of Pharmacy, Oxford, MS, ³MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Women with systemic lupus erythematosus are at an increased risk of infections from the human papillomavirus (HPV) and subsequently HPV-mediated malignancies and genital warts.…
Abstract Number: 2260 • ACR Convergence 2023
Right Insular Cortex-Thalamic Functional Connectivity as a Potential Marker for Fatigue in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Yuichiro fujieda¹, Kodai Sakiyama¹, Nobuya Abe¹, Ryo Hisada¹, Michihito Kono¹, Masaru Kato¹, Olga Amengual², Khin Khin Tha³, Hisashi Shirakawa⁴ and Tatsuya Atsuma⁵, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan, ³Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University Hospital, Sapporo, Japan, ⁴Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto, Japan, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan
Background/Purpose: Fatigue is a common symptom in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). Resting-state functional magnetic resonance imaging (rs-fMRI) has…
Abstract Number: 2276 • ACR Convergence 2023
Patient Reported Impact of Lupus on Quality of Life
Beth Schneider, MyHealthTeam, San Francisco, CA
Background/Purpose: Research was undertaken to better understand how people living with lupus describe its sum total impact on their lives including work, challenges with relationships…
Abstract Number: 2294 • ACR Convergence 2023
Organ Damage Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Richard Furie¹, Eric Morand², Christine Peschken³, Martin Aringer⁴, Laurent Arnaud⁵, Barnabas Desta⁶, Tina Grünfeld Eén⁷, Alessandro Sorrentino⁸, Stephanie Chen⁹ and Bo Ding⁷, ¹Northwell Health, Manhasset, NY, ²Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³University of Manitoba, Winnipeg, MB, Canada, ⁴Carl Gustav Carus, Dresden, Germany, ⁵University Hospitals of Strasbourg, Strasbourg, France, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁸Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ⁹BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: The SLE Prospective Observational Cohort Study (SPOCS) is an international, multicenter study collecting data on patients with SLE, including in relation to oral corticosteroid…
Abstract Number: 2310 • ACR Convergence 2023
Machine Learning Approaches for Prediction of Renal Flares in Systemic Lupus Erythematosus: Knowledge-Driven Models Outperformed Data-Driven Models
Nursen Cetrez¹, Julius Lindblom¹, Raffaele Da Mutten², Dionysis Nikolopoulos² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden
Background/Purpose: Renal flares in patients with SLE result in significant nephron loss. Thus, identification of reliable early signals of impending renal flares is anticipated to…
Abstract Number: 2326 • ACR Convergence 2023
Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g
Emily Littlejohn¹, Salem Almaani², Vanessa Birardi³, Ernie Yap⁴ and Christopher Collins⁵, ¹Cleveland Clinic, Cleveland, OH, ²Ohio State University Medical Center, Columbus, OH, ³Aurinia Pharmaceuticals Inc, Edmonton, AB, Canada, ⁴Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, ⁵Formerly Aurinia Pharmaceuticals Inc., Copenhagen, Denmark
Background/Purpose: Proteinuria is the most common manifestation of lupus nephritis and is a mediator of progressive kidney damage. Early reductions in urine protein creatinine ratio…
Abstract Number: 2346 • ACR Convergence 2023
SLE Medication Usage and Organ Damage Among Adult SLE Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years
Zahi Touma¹, Cristina Arriens², Christine Henning³, Angela Carroll³, Paula Curtis⁴, Roger A. Levy⁵ and William Stohl⁶, ¹University of Toronto, Toronto, ON, Canada, ²Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ³GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁶University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: A key treatment goal for patients (pts) with SLE is to reduce use of CS, due to their association with organ damage.1 BEL is…
Abstract Number: 2459 • ACR Convergence 2023
Reporting of Race and Ethnicity in Lupus Publications in High-impact Rheumatology Journals
Idil Eroglu, Hailey Baker, Mario Felix and Lisa Suter, Yale School of Medicine, New Haven, CT
Background/Purpose: Reporting of race and ethnicity as social constructs is critical to highlight equity and diversity of study participants, with the knowledge that socio-economic factors…
Abstract Number: 2552 • ACR Convergence 2023
Inflammatory Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis
Silvia Malvica¹, Paride Fenaroli², Serena Bagnasco¹, Jeff Hodgin³, Peter Izmirly⁴, H Michael Belmont⁵, Katie Preisinger⁴, Jill Buyon⁶, Larry Magder⁷, Michelle Petri⁸, the Accelerating Medicines Partnership in RA/SLE⁹, Avi Rosenberg¹ and Andrea Fava¹⁰, ¹Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Nephrology and Dialysis Unit, Azienda USL - IRCCS Reggio Emilia, Reggio Emilia, Italy, ³University of Michigan, Ann Arbor, MI, ⁴New York University School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁷University of Maryland, Baltimore, MD, ⁸Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁹Multiple, Multiple, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells. However, this is typically regarded as nonspecific "scar reaction" rather than active…
Abstract Number: 0118 • ACR Convergence 2023
Physical Performance Among Individuals with Systemic Lupus Erythematosus in a Diverse Population-Based Cohort
Courtney Hoge¹, C. Barrett Bowling², Charmayne Dunlop-Thomas¹, Bradley Pearce¹, S. Sam Lim¹, Cristina Drenkard¹ and Laura Plantinga¹, ¹Emory University, Atlanta, GA, ²Duke University, Durham, NC
Background/Purpose: Physical performance is often not measured in clinical settings, despite its association with increased risk of disability, loss of independence, and mortality. Here, we…
Abstract Number: 0183 • ACR Convergence 2023
Barriers and Facilitators to Recruiting Underrepresented Participants for Clinical Trials: Insights from the Lupus Clinical Investigators Network (LuCIN)
Tessa Englund¹, Christine Lee², Julie Hsieh², Richardae Araojo², Julia Mariano¹, Emily McCormick³, Stacie Bell⁴, Albert Roy⁵ and Saira Sheikh¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²U.S. Food and Drug Administration, Silver Spring, MD, ³Thurston Arthritis Research Center, Chapel Hill, NC, ⁴Lupus Therapeutics, Lakewood, CO, ⁵Lupus Research Alliance, New York, NY
Background/Purpose: Despite greater prevalence of lupus among diverse, racial and ethnic minority populations, marked gaps exist between populations affected by lupus and those enrolled in…
Abstract Number: 0462 • ACR Convergence 2023
Breastfeeding Intention in Systemic Lupus Erythematosus Patients
Susana Villamizar Pérez¹, Nicole Josianne Paris¹, Melissa Serna Góngora¹, Ariel Brener¹, Jerson Claros¹, Maria Pia Izaguirre Germain¹, Barbara Pérez Cepas², Marina Micelli³, Gabriel Sequeira¹ and Eduardo Mario Kerzberg¹, ¹Hospital Dr. JM Ramos Mejia, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital medico policial Churruca Visca, Ciudad Autonoma de Buenos Aires, Argentina, ³RELESSAR, CABA, Argentina
Background/Purpose: Breastfeeding in systemic lupus erythematosus (SLE) has received little attention and the limited data available suggest that women with SLE have lower breastfeeding rates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].